Analyst Ratings For Genmab
Analyst Ratings For Genmab
Genmab 的分析师评级
Across the recent three months, 6 analysts have shared their insights on Genmab (NASDAQ:GMAB), expressing a variety of opinions spanning from bullish to bearish.
在最近三个月中，有6位分析师分享了他们对Genmab（纳斯达克股票代码：GMAB）的见解，表达了从看涨到看跌的各种观点。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
下表汇总了他们最近的评级，阐明了过去30天内情绪的变化，并将其与前几个月进行了比较。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $49.67, a high estimate of $50.00, and a low estimate of $48.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.16%.
分析师分析的12个月目标股价提供了见解，平均目标价为49.67美元，最高估计为50.00美元，低估值为48.00美元。随着分析师将平均目标股价下调了0.16％，情绪的负面转变显而易见。
Exploring Analyst Ratings: An In-Depth Overview
探索分析师评级：深入概述
The standing of Genmab among financial...
通过对分析师...
登录免费看全文
登录/注册
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。